THE APEX TIMES
UnitedHealth says an external audit found nearly 97% of HouseCalls diagnoses backed by records
The insurer commissioned FTI Consulting to review diagnosis coding tied to its HouseCalls in-home visits for Medicare Advantage members after scrutiny over whether diagnoses were being overstated for higher payments.
UnitedHealth Group said an external review of its HouseCalls in-home medical visits found that almost 97% of diagnoses identified through the program were supported by patients’ medical records or related paid claims. The company released the results as scrutiny continues around how Medicare Advantage plans use documentation from clinical encounters to support risk-adjusted reimbursements, an issue that has drawn both political and regulatory attention.
HouseCalls is UnitedHealth’s clinician-led program that provides older adults with in-home visits, with the stated goal of surfacing health issues and care gaps that may be missed in traditional office-based appointments. UnitedHealth said the audits concern diagnoses derived from HouseCalls visits that were submitted to the Centers for Medicare & Medicaid Services for Medicare Advantage payment purposes, a process that is central to how insurers are paid based on patients’ health profiles rather than just encounter counts.
According to the company’s disclosures reported by industry media, UnitedHealth engaged FTI Consulting to independently examine diagnosis coding accuracy. FTI randomly sampled 200 HouseCalls visits that were associated with 494 diagnoses. The review concluded that 97% of the diagnoses were supported by documentation in the medical record or by paid claims.
UnitedHealth also said the small share of diagnoses not supported by records and claims was 3.4%. The company characterized that unsupported rate as nearly three times lower than the error rate CMS reported in its most recent Medicare Advantage medical record audit, though it did not provide the underlying CMS audit details in the announcement coverage.
UnitedHealth framed the audit as a response to accusations that HouseCalls generated “trumped up” diagnoses to increase reimbursement. The company did not concede wrongdoing in the disclosures described in the coverage, but it said the independent review was intended to test diagnosis coding practices and reinforce the accuracy of the information used for Medicare Advantage risk adjustment.
In a statement reported by Home Health Care News, UnitedHealth Group CEO Steve Hemsley said HouseCalls visits make up a “small but meaningful” share of the more than 19 million home visits UnitedHealth clinicians make each year. The company also said the program includes follow-up care, including that a majority of participants schedule medical appointments within 90 days after a HouseCalls visit.
Still, several details were not fully spelled out in the coverage. UnitedHealth did not provide, at least in the reported announcement, the full methodology for how diagnoses were categorized, the exact time period for the visits reviewed, or whether the sample was intended to represent all clinical settings and provider types within HouseCalls. The results were described as initial findings from the external examination, with the scope and timing of any further work not clearly stated.
The near-universal diagnosis support rate is likely to be watched by policymakers and auditors given ongoing debate over Medicare Advantage payment accuracy. UnitedHealth’s next steps, including whether it releases more comprehensive findings and how it addresses any remaining error-rate risk, could influence how future scrutiny of risk adjustment documentation evolves for home-based care programs. For now, the company is betting that an independent, randomly sampled chart review will dampen concerns about coding intensity within HouseCalls.
Why It Matters
- Medicare Advantage risk adjustment relies heavily on diagnoses supported by documentation, so audits of coding practices can directly affect how payments are evaluated.
- Home-based clinical programs like HouseCalls are becoming more important for insurers, and reimbursement disputes can reshape how these services are audited and operated.
- An independent review with a randomly sampled chart approach may influence how policymakers assess claims that insurers are over-coding diagnoses for higher payments.
- Even with a high supported-diagnosis rate, a non-zero unsupported percentage can keep regulators and lawmakers focused on documentation controls and error-rate trends.
Sources
Key Facts
- UnitedHealth said an external audit found nearly 97% of HouseCalls diagnoses were supported by medical records or paid claims.
- The review was conducted by FTI Consulting, commissioned by UnitedHealth.
- FTI Consulting randomly sampled 200 HouseCalls visits tied to 494 diagnoses.
- The audit results cited a 3.4% rate of diagnoses that were not supported by medical records or paid claims.
- UnitedHealth said HouseCalls-related diagnoses were submitted to the Centers for Medicare & Medicaid Services as part of Medicare Advantage payment processes.
- UnitedHealth said the HouseCalls program represents a small but meaningful share of more than 19 million home visits UnitedHealth clinicians conduct each year.
- The company said the 3.4% unsupported rate was nearly three times lower than an error rate CMS reported in its most recent Medicare Advantage medical record audit.
Healthcare Related
Eli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fit
The U.S. drugmaker said it will acquire Merida Biosciences in a transaction valued at $2.88 billion, a move that is drawing attention to how Lilly is expanding its pipeline and capabilities.
Eli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipeline
The company agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based consideration.
Eli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansion
The acquisition, reported as worth as much as $2.88 billion, adds another chapter to Lilly’s ongoing buy-or-build approach as biotech rivals also compete for late-stage assets and platform-like capabilities.
Johnson & Johnson schedules investor call for third-quarter results on Oct. 13
The company will hold an investor conference call at 8:30 a.m. Eastern Time to discuss its third-quarter performance, according to a notice posted by Yahoo Finance.
Pfizer reaches confidential settlement in Depo-Provera litigation over alleged meningioma risk
The agreement covers multiple federal lawsuits involving its Depo-Provera contraceptive and claims of an increased risk of intracranial meningioma, according to a report.
Moderna takes August’s S&P 500 win as biotech momentum lifts MRNA shares
A Yahoo Finance review of monthly performance found Moderna leading the S&P 500 in August, rising about 158%, while Edison International finished last, down roughly 27%.
Eli Lilly CEO David Ricks frames its $25B spending push as a long-term bet beyond obesity
In a CNBC interview, Eli Lilly’s chief executive said the company’s recent deal and investment activity is aimed at extending the durability of its obesity franchise and using related technologies to target other diseases through the 2030s, while acknowledging that not every bet will succeed.
Eli Lilly investors weigh valuation after fresh FDA nod, analyst models show mixed picture
A recent market note points to an estimated 30% upside from discounted cash flow modeling, even as other valuation checks look less clear-cut after a new Food and Drug Administration approval.
Eli Lilly shares slide after report of a $2.9 billion acquisition
A market report said Eli Lilly unveiled a $2.9 billion deal tied to its Merida program, prompting investors to reassess near-term valuation and integration risks.
Healthcare’s best week since late June draws focus to a Moderna and Merck cancer trial
A rebound in healthcare equities in the week leading up to Aug. 21 traced back to trading momentum around clinical news tied to Moderna’s work and a Merck cancer study, according to a Yahoo Finance market recap.